Lundbeck Seattle Biopharmaceuticals is a pharmaceutical development company based in Bothell, Washington. Formerly known as Alder Biopharmaceuticals, it specializes in therapeutic monoclonal antibodies.
Overview
In May 2014, Alder went public.[1] In early 2018, the company made a public stock offering, aiming to raise US$250 million.[2] The company identifies, develops, and manufactures antibody therapeutics to alleviate human suffering in cancer, pain, cardiovascular, and autoimmune and inflammatory disease areas.[3]
As of September 2019, the Alder Biopharmaceuticals shares have increased with 83% in price, following the company's acquisition by the Denmark-based H. Lundbeck, in a deal valued at $1.95 billion.[4][5]